NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This is a clinical trial examining the safety, pharmacokinetics, pharmacodynamics and
efficacy of IV NPI-0052 (a proteasome inhibitor) in combination with oral vorinostat
(Zolinza; a HDAC inhibitor) in patients with non-small cell lung cancer, pancreatic cancer,
melanoma or lymphoma. Proteasome inhibitors block the breakdown of proteins by cells and HDAC
inhibitors block modification of proteins regulating gene expression in cells. Both of these
actions preferentially affect cancer cells, and the combination of the two has been seen to
have a greater effect in laboratory studies.
Phase:
Phase 1
Details
Lead Sponsor:
Celgene Triphase Research and Development I Corporation